3.81
+0.08(+2.14%)
Currency In USD
| Previous Close | 3.73 |
| Open | 3.75 |
| Day High | 3.85 |
| Day Low | 3.74 |
| 52-Week High | 7.63 |
| 52-Week Low | 3.38 |
| Volume | 2.18M |
| Average Volume | 2.95M |
| Market Cap | 1.17B |
| PE | 34.64 |
| EPS | 0.11 |
| Moving Average 50 Days | 3.82 |
| Moving Average 200 Days | 5.2 |
| Change | 0.08 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $187.68 as of August 18, 2025 at a share price of $3.81. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $2,202.31 as of August 18, 2025 at a share price of $3.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
GlobeNewswire Inc.
Aug 06, 2025 11:10 AM GMT
Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporati
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
GlobeNewswire Inc.
Jun 09, 2025 8:05 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with en